Tredje AP fonden cut its holdings in Zoetis (NYSE:ZTS) by 1.2% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 356,117 shares of the company’s stock after selling 4,180 shares during the quarter. Zoetis comprises 1.1% of Tredje AP fonden’s holdings, making the stock its 10th biggest position. Tredje AP fonden’s holdings in Zoetis were worth $29,739,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of ZTS. Polen Capital Management LLC acquired a new position in Zoetis during the 4th quarter worth approximately $285,967,000. Bessemer Group Inc. boosted its position in Zoetis by 231,590.8% during the 4th quarter. Bessemer Group Inc. now owns 2,117,654 shares of the company’s stock worth $152,557,000 after acquiring an additional 2,116,740 shares during the last quarter. BlackRock Inc. boosted its position in Zoetis by 3.8% during the 4th quarter. BlackRock Inc. now owns 38,485,542 shares of the company’s stock worth $2,772,498,000 after acquiring an additional 1,394,156 shares during the last quarter. Millennium Management LLC boosted its position in Zoetis by 208.1% during the 4th quarter. Millennium Management LLC now owns 1,984,470 shares of the company’s stock worth $142,961,000 after acquiring an additional 1,340,378 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its position in Zoetis by 111.3% during the 4th quarter. Acadian Asset Management LLC now owns 1,709,352 shares of the company’s stock worth $123,143,000 after acquiring an additional 900,261 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.
In related news, EVP Roxanne Lagano sold 35,663 shares of the stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $81.02, for a total value of $2,889,416.26. Following the sale, the executive vice president now owns 49,919 shares in the company, valued at approximately $4,044,437.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Roman Trawicki sold 23,885 shares of the stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $82.00, for a total value of $1,958,570.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 117,829 shares of company stock worth $9,626,877. 0.35% of the stock is owned by company insiders.
Zoetis opened at $82.75 on Friday, according to MarketBeat. The company has a market capitalization of $40.09 billion, a PE ratio of 31.62, a P/E/G ratio of 1.83 and a beta of 0.97. The company has a debt-to-equity ratio of 2.51, a current ratio of 4.27 and a quick ratio of 2.83. Zoetis has a 12 month low of $82.05 and a 12 month high of $83.07.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Wednesday, May 2nd. The company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.69 by $0.06. Zoetis had a return on equity of 68.51% and a net margin of 17.97%. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.35 billion. During the same quarter in the prior year, the firm posted $0.53 EPS. The firm’s revenue for the quarter was up 11.0% compared to the same quarter last year. sell-side analysts forecast that Zoetis will post 3.06 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 4th. Investors of record on Friday, July 20th will be paid a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a yield of 0.61%. The ex-dividend date is Thursday, July 19th. Zoetis’s dividend payout ratio (DPR) is presently 20.83%.
A number of equities analysts have weighed in on the company. BMO Capital Markets reaffirmed a “hold” rating and set a $80.00 price target on shares of Zoetis in a research report on Wednesday. Cantor Fitzgerald reaffirmed a “buy” rating and set a $98.00 price target on shares of Zoetis in a research report on Wednesday. Craig Hallum reaffirmed a “buy” rating and set a $94.00 price target (up previously from $87.00) on shares of Zoetis in a research report on Wednesday, April 25th. Piper Jaffray reaffirmed a “buy” rating and set a $86.00 price target on shares of Zoetis in a research report on Thursday, January 18th. Finally, ValuEngine raised Zoetis from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and thirteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $82.67.
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.